Lung cancer remains the leading cause of cancer death in the United States with non-small cell lung cancer (NSCLC) accounting for the vast majority (80 – 85 percent) of newly diagnosed cases. Growing knowledge of NSCLC subtypes and molecular biomarkers for this disease has led to changes in how non-small cell lung cancer is diagnosed and staged. This has resulted in more complexity in treatment planning and decision-making, particularly for patients diagnosed with locally advanced stage III and metastatic stage IV disease. Although more treatment options are now available for these patients, fragmentation in the U.S. healthcare system can often impede consistent access to optimal care for all patients diagnosed with locally advanced or metastatic lung cancer.
With this project the Association of Community Cancer Centers (ACCC) will conduct a national multi-phase effort to identify and provide guidance on key issues related to the optimal care for patients diagnosed with stages III and IV non-small cell lung cancer (NSCLC) across different practice settings. The project will explore coordination and communication within the multidisciplinary cancer care team to help oncology teams understand existing barriers and create and execute process improvement plans that address these barriers. The overarching goal will be to support the optimization of care for patients diagnosed with stages III and IV NSCLC.
Fostering Excellence in Care and Outcomes in Patients With Stage III and IV NSCLC with David Spigel, MD - via Targeted Oncology
Association of Community Cancer Centers Collaborates with AstraZeneca to Launch National Initiative to Support Quality Care Initiative for Stage III and IV Non-Small Cell Lung Cancer
This project is made possible by support from AstraZeneca.